Использование ДНК-диагностики в лечебной тактике ведения больных с тромбозом глубоких вен

Objective. Use of DNA diagnostics and the role of genetic mutations most thrombogenic in patients presenting with idiopathic DVT Material and methods. The study analyzes data DNA diagnosis of hereditary thrombophilia and treatment of 75 patients: 60 patients with idiopathic received with idiopathic deep vein thrombosis (DVT) study group, and 15 patients with moderate and high risk of venous thromboembolism (VTE) no signs of DVT after general surgical operations on the abdominal organs performed under endotracheal anesthesia (control group). Results. The necessity of an individual approach to the diagnosis and treatment of patients with DVT based on genetic characteristics. Molecular genetic test of 60 patients diagnosed with DVT possible to establish the relationship between the characteristics of the clinical course a spreading rate of thrombosis and the presence of the most thrombogenic forms of inherited thrombophilia, to determine the duration of antithrombotic therapy. Pharmacogenetic study conducted which resulted in shortening achieved individual dose warfarin was pharmacotherapy and optimization method used in conjunction with other approaches. With this treatment, we carried out in 32 (53.3 %) patients with DVT, replased from different molecular weight heparin and warfarin to rivaroxaban demonstrated efficacy and safety in the absence of hemorrhagic need pharmacogenetic studies for individual dose of rivaroxaban.